Multiple co-culture models represent an advanced approach in oncology research, moving from simplistic 2D cell cultures to dynamic, interactive 3D systems. This sophisticated platform enables the development of physiologically relevant systems incorporating various stromal and immune cells, such as cancer-associated fibroblasts (CAFs), endothelial cells, and tumor-infiltrating lymphocytes. By closely recapitulating the critical cellular crosstalk within the TME, these models elucidate the pivotal role of non-cancerous cells in modulating tumor progression, metastasis, therapeutic resistance, and immune evasion. This platform is indispensable for generating predictive data that bridges the gap between conventional in vitro studies and complex in vivo outcomes.
Based on the spatial architecture and method of interaction between tumor organoids and accessory cells, our co-culture models are categorized to address specific biological questions, from systemic signaling to localized invasion.
Embedded Co-culture
Stromal or immune cells are directly mixed with tumor organoid fragments or cells within a common 3D extracellular matrix (ECM), allowing for intimate, diffuse interactions and the self-organization of a blended microenvironment.
Compartmentalized Co-culture
Utilizing transwell inserts or microfluidic organs-on-chips to physically separate tumor organoids from other cell populations while permitting the exchange of soluble factors. This method is ideal for studying angiogenesis, immune cell migration, and paracrine signaling.
Leveraging extensive expertise in 3D tumor biology and advanced cell culture technologies, Alfa Cytology provides end-to-end multiple co-culture model development and analysis services. Our capability to design, optimize, and validate these complex systems ensures clients receive robust, reproducible, and biologically relevant data tailored to accelerate their specific research and development objectives.
To address the specific tumor microenvironment and therapy responses of different cancers, we have developed a range of disease-specific multiple co-culture models. Representative examples are detailed below:
| Organoid Type | Description |
| Lung Cancer Organoid Co-Culture Model | Co-culture of lung cancer organoids with peripheral blood mononuclear cells (PBMCs), containing T cells, B cells, NK cells, and monocytes, to model comprehensive tumor-immune interactions. |
| Gastric Cancer Organoid Co-Culture Model | Model A: For studying the PD-L1/PD-1 axis, gastric cancer organoids are co-cultured with dendritic cells (DCs) and cytotoxic T lymphocytes (CTLs). |
| Model B: To better model the human immunosuppressive microenvironment, patient-derived gastric cancer organoids are co-cultured with CTLs and myeloid-derived suppressor cells (MDSCs). | |
| Pancreatic Cancer Organoid Co-Culture Model | A multi-component co-culture model integrating pancreatic cancer organoids, CAFs, and PBMCs has been constructed to study stromal-mediated immune cell infiltration in vitro. |
| Colorectal Cancer Organoid Co-Culture Model | Co-culture of colorectal tumor organoids with CAFs and tumor-infiltrating lymphocytes (TILs) to study CAF-mediated chemoresistance and immunotherapy efficacy. |
| Liver Cancer Organoid Co-Culture Model | Generation of histologically complex HCC organoid-like models through co-culture of hepatocellular carcinoma cells with fibroblasts and endothelial cells within a defined ECM. |
| Bladder Cancer Organoid Co-Culture Model | Development of bladder cancer organoids using ultra-low attachment plates by co-culturing carcinoma cells with primary human bladder stromal cells (fibroblasts and smooth muscle cells). |
| … | … |
Alfa Cytology specializes in developing customized, organoid-based multiple co-culture models utilizing a suite of advanced methodologies tailored to your specific research goals in drug testing, immunotherapy assessment, and mechanistic studies.
Alfa Cytology offers a comprehensive suite of research services leveraging our advanced organoid-based co-culture platforms to support projects from mechanism discovery to translational application. Our team tailors each study to interrogate complex tumor-stroma-immune interactions within a highly relevant human model system.
Focused on elucidating fundamental biology, our services include investigating TME-mediated signaling pathway activation, characterizing stromal-induced phenotypic shifts in organoids, mapping immune cell recruitment and exhaustion dynamics, and deciphering the molecular underpinnings of therapy resistance.
Designed to accelerate therapeutic development, our services encompass candidate drug efficacy and combination screening in a physiologically relevant TME context, assessment of drug penetration and specificity, evaluation of novel immunotherapies (e.g., T-cell engagers, bispecific antibodies), and biomarker discovery for individual stratification.
To demonstrate the application of our co-culture platform, a study was developed focusing on gastric cancer. Gastric cancer organoids were successfully generated from tumor tissues and co-cultured with autologous immune cells, specifically cytotoxic T lymphocytes (CTLs) and myeloid-derived suppressor cells (MDSCs) isolated from the same donor. This autologous model was then utilized to evaluate the efficacy of different therapeutic combinations. The results demonstrated that a single targeted agent (Drug A) had a limited effect on organoid viability in the immunosuppressive milieu sustained by MDSCs. Significant organoid death was observed only when this agent was combined with either an anti-PD1 immune checkpoint inhibitor (Drug B) or an anti-HER2 targeted therapy (Drug C). This study conclusively showed that our autologous co-culture system successfully recapitulated key resistance mechanisms and served as a powerful in vitro tool for assessing the efficacy of tailored combination regimens, underscoring its potential for guiding personalized therapy strategies.
Fig.1 Quantification of organoid area in autologous gastric cancer organoid/CTL/MDSC co-cultures following therapy with different therapeutic regimens. Data are presented as mean ± SEM (n=6; *p < 0.05).
Advancing cancer research requires models that reflect the complexity of human disease. Alfa Cytology's specialized multiple co-culture models service provides the sophisticated, physiologically relevant tools necessary to uncover novel biology and develop more effective therapies with greater predictive power. To discuss how our customized co-culture development and research services can advance your specific oncology program, please contact our scientific team to begin a collaborative dialogue.
Reference
For research use only.
Alfa Cytology is a preclinical research service provider specializing in tumor organoid development. We provide one-stop services that include tailored 3D cancer models, organoid-based research services, and related products to accelerate the discovery and development of cancer therapeutics.
Copyright © 2026 Alfa Cytology. All rights reserved.